BSX · 8-K · 20261028PR000066
Operating Income and Margins
BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 55 · Surprise 66 · From source text
Third-quarter operating income fell 21.0% to $828 million from $1.048 billion, while operating margin declined to approximately 16.1% from 20.7%. Total operating expenses rose to $2.600 billion from $2.494 billion, with $81 million of litigation-related net charges and $63 million of restructuring net charges in 2026, compared with no litigation charge and an $8 million restructuring credit in 2025. SG&A decreased 3.3% to $1.683 billion, while R&D increased 1.2% to $520 million; the release does not specify drivers for these changes.
Key facts
- Boston Scientific recorded Q3 2026 operating income of $828 million, compared with $1.048 billion in Q3 2025. source
- Boston Scientific reported nine-month 2026 operating income of $3.107 billion, compared with $2.788 billion in the first nine months of 2025. source
- Boston Scientific recorded Q3 2026 litigation-related net charges of $81 million; no amount was reported for Q3 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | realized | +5.9% | Boston Scientific reported nine-month 2026 operating income of $3.107 billion, compared with $2.788 billion in the first nine months of… |